… S-protein that can prevent SARS-CoV-2 infection and pneumonia in mice. Single intranasal
administration of the vaccine was studied in a stringent SARS-CoV-2 challenge model in …

… full-length SARS-CoV-2 protein administered via intranasal … immunogenicity of an intranasal
immunized SARS-CoV-2 … immunized with a recombinant SARS-CoV-2 RBD adjuvanted …

… Our findings imply that intranasal administration of RBD immunogens directed … intranasal
administration may not only prevent mucosal infection but also limit subsequent SARS-CoV-2 …

… doses, with both IM and intranasal routes. Su et al. used … intranasal booster vaccines. Both
groups showed efficient immune responses against SARS-CoV-2 infection, and the intranasal …

… an intranasally administered spike protein-based chimpanzee adenovirus-vectored vaccine
(ChAd-SARS-CoV-2-… A single intranasal dose of ChAd-SARS-CoV-2-S induced durably high …

… Here we show that intranasally administered LNA ASOs represent a promising therapeutic
strategy for virus-induced respiratory diseases such as COVID-19. Importantly, our study …

… in VAED following SARS-CoV-2 infection. Our data showed that intranasal administration of
… These data therefore indicated that intranasal administration of AdCOVID did not potentiate …

… that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 …
After 5 days post-exposure to SARS-CoV-2, INNA-051 significantly reduced virus in throat …

… We report that a single intranasal administration of AdCOVID significantly decreased the
copies of viral RNA in SARS-CoV-2 challenged mice compared to vehicle controls. AdCOVID …

… as SARS-CoV and MERS-CoV to which our populations have little or no immunity was
highlighted by SARS … , no agents have been approved for treating SARS-CoV or MERS-CoV. …